The Oncotype DX® Recurrence Score® result is a robust predictor of loco-regional recurrence in node-positive, estrogen receptor (ER)-positive patients treated with adjuvant hormonal therapy and chemotherapy, according to the results of a study presented at the 2013 Society of Surgical Oncology Annual Cancer Symposium in National Harbor, Maryland.
Among women with early-stage breast cancer, the expression, or activity, of certain genes has been linked with the likelihood of cancer recurrence. Oncotype DX is a genomic test that predicts risk of recurrence among selected women with early-stage breast cancer. The test evaluates 21 genes in a sample of tumor tissue and generates a recurrence score. The information provided by the Recurrence Score can help guide treatment decisions.
This study analyzed tumor samples from 1,065 ER-positive, node-positive breast cancer patients who were treated with hormonal therapy and chemotherapy as part of a clinical trial known as NSABP B-28.
After a median follow-up of 11.2 years, 80 patients had local (68 percent) or regional (32 percent) recurrence. The 10-year cumulative incidence of loco-regional recurrence was 3.3 percent for patients with a low Recurrence Score (RS) result, 7.2 percent for those with an intermediate RS result, and 12.3 percent for those with high RS result.
These results indicate that the Oncotype DX Recurrence Score predicts risk of recurrence and survival outcomes among women with ER-positive, node-positive breast cancer treated with chemotherapy and hormone therapy. High-risk women may benefit from more extensive treatment or enrollment in a clinical trial.
The study results suggest that Oncotype DX could be valuable in tailoring radiation therapy treatment for select node-positive patients treated with hormonal therapy and chemotherapy. Assessing a patient’s risk could help physicians determine the most appropriate treatment plan.
Mamounas EP, Tang G, Paik S, et al. The 21-gene Recurrence Score (RS) Predicts Risk of Loco-regional Recurrence (LRR) in Node (+), ER (+) Breast Cancer (BC) Dfter Adjuvant Chemotherapy and Tamoxifen: Results from NSABP B-28. Ann Surg Oncol (2013) 20:S6–S164. Abstract 2.
Copyright © 2017 CancerConsultants. All Rights Reserved.